S4 Ep3: Transforming Alzheimer's disease diagnosis through blood tests with Dr. Joel Braunstein, CEO and Co-founder of C2N Diagnostics
This week on Tech Can’t Save Us, host Paul David is joined by Dr. Joel Braunstein, co-founder, CEO, and president of C2N Diagnostics, a pioneering biotech company transforming the way we diagnose Alzheimer’s disease.
They explore how C2N is advancing blood-based diagnostic tools, most notably the Precivity AD test that delivers accuracy comparable to PET scans and spinal taps, but in a simpler, less invasive format. Joel shares how these innovations are reducing misdiagnosis rates, empowering clinicians, and providing families with clarity during some of their most difficult moments.
Joel…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.